JP2017521398A5 - - Google Patents

Download PDF

Info

Publication number
JP2017521398A5
JP2017521398A5 JP2016574169A JP2016574169A JP2017521398A5 JP 2017521398 A5 JP2017521398 A5 JP 2017521398A5 JP 2016574169 A JP2016574169 A JP 2016574169A JP 2016574169 A JP2016574169 A JP 2016574169A JP 2017521398 A5 JP2017521398 A5 JP 2017521398A5
Authority
JP
Japan
Prior art keywords
acid
process according
alkyl
aryl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016574169A
Other languages
English (en)
Japanese (ja)
Other versions
JP6581607B2 (ja
JP2017521398A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/036017 external-priority patent/WO2015195656A2/en
Publication of JP2017521398A publication Critical patent/JP2017521398A/ja
Publication of JP2017521398A5 publication Critical patent/JP2017521398A5/ja
Application granted granted Critical
Publication of JP6581607B2 publication Critical patent/JP6581607B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016574169A 2014-06-20 2015-06-16 多環式カルバモイルピリドン化合物の合成 Active JP6581607B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462015081P 2014-06-20 2014-06-20
US62/015,081 2014-06-20
PCT/US2015/036017 WO2015195656A2 (en) 2014-06-20 2015-06-16 Synthesis of polycyclic-carbamoylpyridone compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019157816A Division JP6880127B2 (ja) 2014-06-20 2019-08-30 多環式カルバモイルピリドン化合物の合成

Publications (3)

Publication Number Publication Date
JP2017521398A JP2017521398A (ja) 2017-08-03
JP2017521398A5 true JP2017521398A5 (enExample) 2018-07-19
JP6581607B2 JP6581607B2 (ja) 2019-09-25

Family

ID=53674256

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016574169A Active JP6581607B2 (ja) 2014-06-20 2015-06-16 多環式カルバモイルピリドン化合物の合成
JP2019157816A Active JP6880127B2 (ja) 2014-06-20 2019-08-30 多環式カルバモイルピリドン化合物の合成

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019157816A Active JP6880127B2 (ja) 2014-06-20 2019-08-30 多環式カルバモイルピリドン化合物の合成

Country Status (21)

Country Link
US (3) US20150368264A1 (enExample)
EP (3) EP3527573B9 (enExample)
JP (2) JP6581607B2 (enExample)
KR (2) KR101975912B1 (enExample)
CN (3) CN106470975B (enExample)
AR (2) AR100904A1 (enExample)
AU (3) AU2015277312B2 (enExample)
BR (2) BR122021009062B1 (enExample)
CA (2) CA2950300C (enExample)
EA (2) EA201992183A3 (enExample)
ES (2) ES2821143T3 (enExample)
IL (3) IL249134B (enExample)
MX (2) MX363532B (enExample)
NZ (1) NZ726859A (enExample)
PL (2) PL3157933T3 (enExample)
PT (2) PT3157933T (enExample)
SG (2) SG10201912040RA (enExample)
SI (2) SI3157933T1 (enExample)
TR (1) TR201906366T4 (enExample)
TW (2) TWI744723B (enExample)
WO (1) WO2015195656A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3067358T3 (da) 2012-12-21 2019-11-04 Gilead Sciences Inc Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse
US9856271B2 (en) 2014-01-21 2018-01-02 Laurus Labs Limited Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) * 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (enExample) 2014-06-20 2018-06-23
BR102016026127A2 (pt) 2015-11-09 2017-05-16 Gilead Sciences Inc composições terapêuticas para o tratamento do vírus da imunodeficiência humana
ZA201803942B (en) 2017-06-13 2021-05-26 Cipla Ltd Novel processes for preparation of integrase inhibitor
CN109020911B (zh) * 2018-04-16 2022-06-28 常州制药厂有限公司 用于制备bictegravir的中间体及其制备方法
CN108774145A (zh) * 2018-05-23 2018-11-09 安徽华昌高科药业有限公司 一种(1r,3s)-3-氨基环戊醇盐酸盐的制备方法
WO2020003151A1 (en) 2018-06-28 2020-01-02 Honour Lab Limited Process for the preparation of sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1', 2':4,5]pyrazino[2,1-b] [1,3] oxazepin-8-olate and its polymorphic form
WO2020012408A2 (en) * 2018-07-12 2020-01-16 Laurus Labs Limited A process for purification of protected polycyclic carbamoylpyridone derivatives
CN110862325B (zh) * 2018-08-28 2020-08-25 重庆博腾制药科技股份有限公司 一种(1r,3s)-3-氨基-1-环戊醇及其盐的制备方法
CN111018725B (zh) * 2018-10-09 2023-07-07 上海迪赛诺化学制药有限公司 一种（1r,3s）-3-氨基环戊醇手性酸盐的制备方法
EA202191890A1 (ru) 2019-01-18 2022-02-03 Астразенека Аб Ингибиторы pcsk9 и способы их применения
CN109868293A (zh) * 2019-01-22 2019-06-11 湖南理工学院 一种酶催化酯交换动力学拆分2-氯扁桃酸对映体的方法
CN110041210A (zh) * 2019-05-06 2019-07-23 凯瑞斯德生化(苏州)有限公司 一种Bictegravir中间体及其制备方法
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
CN111056939B (zh) * 2019-10-16 2022-08-05 弈柯莱生物科技(上海)股份有限公司 一种(1r,3s)-3-氨基环戊醇及其中间体的制备方法
CN112174929A (zh) * 2020-10-13 2021-01-05 台州市生物医化产业研究院有限公司 一种西他列汀关键中间体热解杂质及其制备方法和应用
WO2025184448A2 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788516A (fr) 1971-09-10 1973-03-07 Lonza Ag Procede de fabrication d'esters alcoxyacetylacetiques
GB1528382A (en) 1974-12-26 1978-10-11 Teijin Ltd Cyclopentene diols and acyl esters thereof and processes for their preparation
DE2658401A1 (de) 1976-12-23 1978-07-06 Merck Patent Gmbh Cyclopentan-1-amine, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
US4575694A (en) 1984-03-05 1986-03-11 Allied Corporation Coaxial connector
GB8729994D0 (en) 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
DE3900735A1 (de) * 1989-01-12 1990-07-26 Hoechst Ag Neue mehrfunktionelle (alpha)-diazo-(beta)-ketoester, verfahren zu ihrer herstellung und deren verwendung
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
DE4014649A1 (de) * 1990-05-08 1991-11-14 Hoechst Ag Neue mehrfunktionelle verbindungen mit (alpha)-diazo-ss-ketoester- und sulfonsaeureester-einheiten, verfahren zu ihrer herstellung und deren verwendung
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
FR2734822B1 (fr) 1995-05-30 1997-07-04 Rhone Poulenc Rorer Sa Nouveaux derives du 2-azabicyclo(2.2.1)heptane, leur preparation et leur application
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
SE9603285D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
WO1998045268A1 (en) 1997-04-04 1998-10-15 Pfizer Products Inc. Nicotinamide derivatives
SE9702772D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
AU1403099A (en) * 1997-11-14 1999-06-07 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
BR9915194A (pt) * 1998-11-09 2001-08-07 Black James Foundation Composto, método para fabricar o mesmo, composição farmacêutica, e, método para fabricar a mesma
GB2345058A (en) 1998-12-01 2000-06-28 Cerebrus Pharm Ltd Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system
US6620841B1 (en) 1998-12-25 2003-09-16 Shionogi & Co., Ltd. Aromatic heterocycle compounds having HIV integrase inhibiting activities
AU2001262732A1 (en) 2000-06-14 2001-12-24 Shionogi And Co., Ltd. Inhibitor for enzyme having two divalent metal ions as active centers
CA2417277A1 (en) 2000-07-27 2002-02-07 F. Hoffmann-La Roche Ag 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3.beta.
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
EP2181985B1 (en) 2001-08-10 2011-10-26 Shionogi & Co., Ltd. Antiviral Agent
TWI335221B (en) 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
NZ532018A (en) 2001-10-03 2004-12-24 Ucb S Pyrrolidinone derivatives
CA2463976C (en) 2001-10-26 2007-02-13 Benedetta Crescenzi N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
WO2004004657A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Hiv integrase inhibitors
JP2006506352A (ja) 2002-09-11 2006-02-23 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害剤として有用なジヒドロキシピリドピラジン−１，６−ジオン化合物
JP2006514003A (ja) 2002-10-30 2006-04-27 メルク　エンド　カムパニー　インコーポレーテッド ケモカイン受容体活性のテトラヒドロピラニルシクロペンチルベンジルアミド調節剤
AR042095A1 (es) 2002-11-20 2005-06-08 Japan Tobacco Inc Compuesto 4-oxoquinolina y aplicacion del mismo como inhibidor de integrasa de vih
US20040224917A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
CN101014571A (zh) 2004-01-30 2007-08-08 默克公司 用作hiv整合酶抑制剂的n－苄基－3,4－二羟基吡啶－2－羧酰胺类和n－苄基－2,3－二羟基吡啶－4－羧酰胺类化合物
CN101014574A (zh) 2004-03-09 2007-08-08 默克公司 Hiv整合酶抑制剂
EP1755586A2 (en) 2004-04-29 2007-02-28 The Regents of the University of California Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors
WO2005110399A2 (en) 2004-04-29 2005-11-24 The Regents Of The University Of California Zinc-binding groups for metalloprotein inhibitors
CN1964975B (zh) 2004-05-07 2011-11-30 默沙东公司 Hiv整合酶抑制剂
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
WO2005113509A1 (en) 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2005112930A1 (en) 2004-05-21 2005-12-01 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and anti-hiv agents
US7550463B2 (en) 2004-09-15 2009-06-23 Shionogi & Co., Ltd. Carbamoylpyridone derivatives having inhibitory activity against HIV integrase
JP2006118669A (ja) 2004-10-25 2006-05-11 Sanoh Industrial Co Ltd 樹脂チューブ
WO2006066414A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
EP1852434B1 (en) 2005-02-21 2011-07-13 Shionogi Co., Ltd. Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity
JP4295353B2 (ja) 2005-04-28 2009-07-15 スミスクライン ビーチャム コーポレーション Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
WO2006125048A2 (en) 2005-05-16 2006-11-23 Gilead Sciences, Inc. Hiv-integrase inhibitor compounds
CA2616314A1 (en) 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of hiv
JP5131689B2 (ja) 2005-10-27 2013-01-30 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
SG170796A1 (en) 2005-12-30 2011-05-30 Gilead Sciences Inc Us Methods for improving the pharmacokinetics of hiv integrase inhibitors
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
EP2452682A1 (en) 2006-02-01 2012-05-16 Japan Tobacco, Inc. Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
WO2007099385A1 (en) 2006-03-01 2007-09-07 Glenmark Pharmaceuticals S.A. Dipeptidyl peptidase iv inhibitor compounds and compositions
US8420821B2 (en) 2006-03-06 2013-04-16 Japan Tobacco Inc. Process for production of 4-oxoquinoline compound
AU2007223260C1 (en) 2006-03-06 2011-02-03 Japan Tobacco Inc. Method for producing 4-oxoquinoline compound
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
JP2009543865A (ja) 2006-07-19 2009-12-10 ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド ピリジノンジケト酸：併用療法におけるｈｉｖ複製の阻害剤
MX2009002689A (es) 2006-09-12 2009-03-26 Gilead Sciences Inc Proceso e intermediarios para preparar inhibidores de integrasa.
US20100216834A1 (en) 2006-10-18 2010-08-26 Isaacs Richard C A Hiv integrase inhibitors
UA98777C2 (en) 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
ES2602784T3 (es) 2007-02-23 2017-02-22 Gilead Sciences, Inc. Moduladores de las propiedades farmacocinéticas de los agentes terapéuticos
US20080280945A1 (en) 2007-05-09 2008-11-13 Sachin Lohani Crystalline forms of an HIV integrase inhibitor
EP2167088A1 (en) 2007-06-29 2010-03-31 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
KR20100028656A (ko) 2007-06-29 2010-03-12 길리애드 사이언시즈, 인코포레이티드 치료 조성물 및 그의 용도
CA2693340A1 (en) 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Pyrone analog compositions and methods
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
GB0803019D0 (en) 2008-02-19 2008-03-26 Btg Int Ltd Fluorinated compounds
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
EP2271629A1 (en) * 2008-04-22 2011-01-12 AstraZeneca AB Substituted pyrimidin-5-carboxamides 281
US20100272811A1 (en) 2008-07-23 2010-10-28 Alkermes,Inc. Complex of trospium and pharmaceutical compositions thereof
WO2010011819A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011812A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011815A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
EP2320909B8 (en) 2008-07-25 2016-03-30 VIIV Healthcare Company Chemical compounds
WO2010011816A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011818A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
EP3210603A1 (en) 2008-12-11 2017-08-30 Shionogi & Co., Ltd Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
WO2010068262A1 (en) * 2008-12-11 2010-06-17 Glaxosmithkline Llc Processes and intermediates for carbamoylpyridone hiv integrase inhibitors
WO2010110231A1 (ja) 2009-03-26 2010-09-30 塩野義製薬株式会社 置換された３－ヒドロキシ－４－ピリドン誘導体
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
PL2444400T3 (pl) 2009-06-15 2018-08-31 Shionogi & Co., Ltd. Podstawiona policykliczna pochodna karbamoilopirydonowa
WO2011028044A2 (ko) * 2009-09-02 2011-03-10 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
NZ627827A (en) 2010-01-27 2016-02-26 Viiv Healthcare Co Antiviral combinations involving (3s, 11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
SG183484A1 (en) 2010-02-26 2012-09-27 Japan Tobacco Inc 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
WO2012009009A2 (en) 2010-07-14 2012-01-19 Addex Pharma S.A. Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
EP3127908B1 (en) 2010-08-05 2018-11-28 Shionogi & Co., Ltd Process for preparing compound having hiv integrase inhibitory activity
HRP20181250T1 (hr) 2010-09-24 2018-10-05 Shionogi & Co., Ltd. Predlijek iz supstituiranog policikličkog derivata karbamoilpiridona
WO2012106534A2 (en) 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
US20140213553A1 (en) 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2012151567A1 (en) 2011-05-05 2012-11-08 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for preventing and treating influenza
US9121496B2 (en) 2011-06-29 2015-09-01 Arvinmeritor Technology, Llc Drive axle system and a method of control
PL2742051T3 (pl) 2011-09-14 2017-06-30 Mapi Pharma Limited Amorficzna postać soli sodowej dolutegrawiru
US9246434B2 (en) 2011-09-26 2016-01-26 First Solar, Inc System and method for estimating the short circuit current of a solar device
EP2774928B1 (en) 2011-10-12 2017-08-30 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
CN104114559B (zh) * 2011-12-12 2016-08-24 拜耳知识产权有限责任公司 氨基取代的咪唑并哒嗪
EA026368B1 (ru) 2011-12-21 2017-03-31 Новира Терапьютикс, Инк. Противовирусные агенты против гепатита в
WO2014008636A1 (en) 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
US20150166520A1 (en) 2012-07-20 2015-06-18 Merck Sharp & Dohme Corp. Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection
US20150218164A1 (en) 2012-07-25 2015-08-06 Merck Sharp & Dohme Corp. Substituted naphthyridinedione derivatives as hiv integrase inhibitors
US8877931B2 (en) 2012-08-03 2014-11-04 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
SG11201503397YA (en) * 2012-11-08 2015-05-28 Bristol Myers Squibb Co Heteroaryl substituted pyridyl compounds useful as kinase modulators
MA38182A1 (fr) 2012-12-14 2018-04-30 Glaxosmithkline Llc Compositions pharmaceutiques a action prolongée pur une utilisation dans le traitement ou la prévention d'infections par le virus de l’immunodéficience humaine (vih)
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
US20140221355A1 (en) 2012-12-21 2014-08-07 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
DK3067358T3 (da) * 2012-12-21 2019-11-04 Gilead Sciences Inc Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse
EP2934482A4 (en) 2012-12-21 2016-07-20 Merck Sharp & Dohme ADMINISTRATIVE FORMULATIONS
SG11201504982PA (en) 2012-12-27 2015-07-30 Japan Tobacco Inc SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR
US9951079B2 (en) 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
PL3019503T3 (pl) 2013-07-12 2018-01-31 Gilead Sciences Inc Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
EP3049081B1 (en) 2013-09-27 2019-11-27 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
JP6515113B2 (ja) 2013-11-25 2019-05-15 ケィティ、コーポレーションＫｔ Ｃｏｒｐｏｒａｔｉｏｎ ホームネットワーク伝送線路の干渉緩和装置、干渉緩和方法およびこれを用いた通信システム
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
US9856271B2 (en) 2014-01-21 2018-01-02 Laurus Labs Limited Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
NO2717902T3 (enExample) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) * 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成

Similar Documents

Publication Publication Date Title
JP2017521398A5 (enExample)
CN103476762B (zh) 用于生产曲前列环素的中间体的合成
JP5368971B2 (ja) リン含有α−ケト酸の製造法
BRPI0612803A2 (pt) processo para preparar um composto
JP2007504191A (ja) スチルベン誘導体を製造する方法
RU2012122367A (ru) Способ получения простагландинов и промежуточные соединения для их получения
CN103562170B (zh) 经由克莱森重排制备双环化合物的方法
CN103582622B (zh) 经由亚胺鎓盐制备双环化合物的方法
JP2016517886A5 (enExample)
JP2013534911A5 (enExample)
US9388158B2 (en) Production method for cyclopentanone derivative, intermediate compound, and production method for intermediate compound
KR20160096636A (ko) 레가데노손의 제조를 위한 방법
CN104926868B (zh) 一种制备吲哚膦酸酯衍生物的方法
JP2012509267A (ja) （Ｒ）−３−（２，３−ジヒドロキシプロピル）−６−フルオロ−５−（２−フルオロ−４−ヨードフェニルアミノ）−８−メチルピリド［２，３−ｄ］ピリミジン−４，７（３Ｈ，８Ｈ）−ジオン及びその中間体を製造するためのプロセス
CN106414389B (zh) 从1,1,1‑三氟丙酮制备4‑烷氧基‑1,1,1‑三氟丁‑3‑烯‑2‑酮的方法
CN113968786B (zh) 两种甲基取代的2-氧代-3-环戊烯-1-羧酸酯化合物的制法及制备用二羧酸酯化合物
JP6476591B2 (ja) （２Ｒ）−２−フルオロ−２−Ｃ−メチル−Ｄ−リボノ−γ−ラクトン類の製造方法
JP2000026365A (ja) シキミ酸およびその誘導体の製造方法
JP2011074063A5 (enExample)
KR101130717B1 (ko) ＨＭＧ-ＣｏＡ 환원 저해제의 제조를 위한 키랄 중간체의제조방법
JPWO2017056501A1 (ja) 酸ハライド溶液の製造方法、混合溶液、及びモノエステル化合物の製造方法
Andrade et al. An efficient synthesis of D-galactose-based multivalent neoglycoconjugates
US7595418B2 (en) Protected 5,7-dihydroxy-4,4-dimethyl-3-oxoheptanoic acid esters and 5,7-dihydroxy-2-alkyl-4,4-dimethyl-3-oxoheptanoci acid esters for the synthesizing of epothilone and epothilone derivatives and process for the production of these esters
JP5419075B2 (ja) ２−アシロキシ−１，７，８−トリフルオロナフタレン誘導体及びその製造方法
KR102692932B1 (ko) 2-((6-(히드록시메틸)크로멘-5-일)옥시)-1-페닐에타논 유도체의 합성 방법